文献速递抗栓抗凝管理

英格兰NHS信托中andexanet alfa用于逆转直接口服抗凝药的趋势与差异

Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England.
PubMed 文献 · Br J Clin Pharmacol · 2025-12-17

研究利用OpenPrescribing Hospitals平台分析英格兰NHS信托药房库存数据,评估2021年5月至2025年6月andexanet alfa的使用趋势。

要点

  • 各NHS信托间启用时间与速度差异大,地区间差异也显著。
  • 该研究首次基于OpenPrescribing Hospitals平台分析新疗法采纳情况。

核心结论

  • andexanet alfa在英格兰NHS各地区及信托间的使用存在显著差异。

研究设计与样本

  • 利用OpenPrescribing Hospitals平台分析英格兰NHS信托药房库存控制数据(Secondary Care Medicines Dataset),限24小时顾问主导急诊活动的信托。

主要发现

  • 各NHS信托间启用时间与速度差异大。
  • 英格兰各NHS地区间使用差异显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life-threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK-wide survey of local hospital protocols for the use of andexanet alfa suggested that practice across the United Kingdom is highly variable. In January 2025, NICE was unable to make a recommendation on the use of andexanet alfa for reversing anticoagulation in adults with intracranial haemorrhage. We set out to report trends and variation in the uptake of andexanet alfa across the NHS in England, using the new OpenPrescribing Hospitals platform. METHODS: To assess the uptake of andexanet alfa, we analysed pharmacy stock control data from NHS trusts in England using the openly available Secondary Care Medicines Dataset. Analysis was restricted to NHS trusts with 24-h consultant-led emergency care activity. RESULTS: Between May 2021 and June 2025, 19 608 vials of andexanet alfa were issued in NHS trusts in England. There was wide variation in the timing and speed of uptake across NHS trusts. Substantial variation was also observed between NHS Regions in England. CONCLUSIONS: The use of andexanet alfa varies markedly between NHS regions and between NHS trusts in England. This study is the first analysis of adoption of a new treatment using the OpenPrescribing Hospitals platform, which is expected to provide a generalizable framework for similar analyses in the future.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Fisher L, Buka R, Byrne R, et al. Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England. Br J Clin Pharmacol. 2025. PMID: 41406988. doi:10.1002/bcp.70417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。